^
Association details:
| Biomarker: | HR positive |
|---|---|
| Cancer: | HER2 Negative Breast Cancer |
| Drug: | Focus V (anlotinib) (Multi-tyrosine kinase inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
The Efficacy and Safety of Anlotinib Combined With Fulvestrant in Patients With Advanced Breast Cancer
Excerpt:
...- Histology confirmed HR-positive and HER2-negative locally advanced or metastatic breast cancer;...
Trial ID:
Source:
Title:
A Controlled, Phase II Study of Anlotinib vs Placebo Combination with Vinorelbine for the Treatment of HER2- Advanced Breast Cancer
Excerpt:
...Enrolled patients were HER2-negative breast cancer patients who had failed to prior taxane and/or anthracycline therapy, or patients with hormone receptor-positive HER2-negative advanced breast cancer who had progressed with at least prior first-line endocrine therapy; 6. ...
Trial ID:
More C2 evidence
Source:
Title:
A prospective study on efficacy and safety of anlotinib combined with fulvestrant in patients with HR-positive and HER2-negative, secondary endocrine-resistant, locally advanced or metastatic breast cancer
Excerpt:
...HR-positive and HER2-negative breast cancer diagnosed by histology; 5. ...
Trial ID:
Source:
Title:
Anlotinib Combination With Vinorelbine in the HER2- Advanced Breast Cancer
Excerpt:
...Enrolled patients were HER2-negative breast cancer patients who had failed to prior taxane and/or anthracycline therapy, or patients with hormone receptor-positive HER2-negative advanced breast cancer who had progressed with at least prior first-line endocrine therapy;...
Trial ID:
Source:
Title:
Clinical study on the treatment of second-line and above HER2 negative advanced breast cancer with anrotinib combined with capecitabine
Excerpt:
......
Trial ID:
Less C2 evidence
Source:
Title:
452P - A phase II trial of anlotinib and fulvestrant in patients with metastatic breast cancer previously treated with an aromatase inhibitor
Published date:
10/16/2023
Excerpt:
The key enrolled criteria were women aged 18 years or older of any menopausal status (premenopausal or perimenopausal women received ovarian function suppression), ECOG PS 0-1, histologically confirmed HR-positive and HER2-negative breast cancer...After a median follow-up time of 5.5 months (95% CI, 3.4-7.6), 21 pts had the confirmed best overall response assessments which inferred the ORR of 19.0% (PR in 4 pts. 95% CI, 5.4-41.9) and the DCR of 81.0% (PR in 4 pts and SD in 13 pts. 95% CI, 58.1-94.6)....Anlotinib combined with fulvestrant showed a promising efficacy with an acceptable safety profile for patients with metastatic breast cancer previously treated with AI.
Secondary therapy:
fulvestrant
Trial ID:
Source:
Title:
Efficacy and safety of anlotinib-based treatment in metastatic breast cancer patients
Published date:
12/09/2022
Excerpt:
The median PFS time of a total of 56 patients was 5.7 months (95% CI, 3.17-8.22months). The ORR and DCR was 28.6% and 71.4%, respectively. In second-line, third-line, and beyond treatment, the median PFS was 11.7 months, 8.7 months, and 4.7 months, respectively. In different subtype of breast cancer, the median PFS was 5.6 months, 5.7months, and 6.4 months in human epidermal growth factor receptor 2 positive (HER2+), hormone receptor positive and HER2 negative (HR+/HER2-), and triple negative breast cancer (TNBC) patients, respectively....Anlotinib-based treatment showed good efficacy and manageable toxicity in multi-line treatment of MBC patients who failed the standard treatment.
DOI:
https://doi.org/10.3389/fonc.2022.1042451
